News from the Institute

In a new publication in Nature Communications, a team of researchers from IBC2 at Goethe University Frankfurt, reports the first comprehensive, data-driven classification of all human E3 ubiquitin ligases. The study presents a systematic map of the human “E3 ligome” and provides new insights into the functional relationships among E3 ligases.

We are thrilled to welcome our new Leica STELLARIS FALCON confocal laser-scanning microscope with integrated fluorescence lifetime imaging (FLIM) to our institute and are eager to begin exploring its full potential for our research.
This state-of-the-art imaging platform will significantly enhance imaging-based research in biochemistry, molecular biology and biomedicine. It combines a flexible white light laser with highly sensitive hybrid detectors and advanced FLIM capabilities, enabling fast, high-resolution and quantitative imaging in living cells. The system supports sophisticated applications such as FRET-based measurements and functional imaging based on fluorescence lifetimes.
 

For the eighth consecutive year, IBC2 Director Ivan Đikić has been named as a Highly Cited Researcher, recognizing his outstanding influence in the life sciences. His research papers have ranked among the most cited from 2014 to 2024 in the two categories “Biology and Biochemistry” and “Molecular Biology and Genetics”, as recorded by Web of Science.

The first Rhine Main Universities (RMU) Award for Pharmaceutical Research & Innovative Medical Therapies, sponsored by the Frankfurt Foundation Quality of Medicines, will go to IBC2 scientist Cristian Prieto-Garcia from the Dikic group. The award recognizes his groundbreaking work uncovering how deregulated RNA splicing drives proteotoxicity, opening new therapeutic avenues.

In their recent review (published in Trends in Pharmacological Sciences) IBC2 researchers Gina Gotthardt, Jan Keiten-Schmitz, and IBC2 Vice Director Stefan Müller discuss how SUMO-signaling and SUMO-targeted ubiquitin ligases (StUbLs) can be exploited to inactivate disease-associated proteins. The review explores the new therapeutic possibilities that this opens within the field of drug discovery utilizing the ubiquitin-proteasome system.